
- /
- Supported exchanges
- / US
- / SKYE.NASDAQ
Skye Bioscience, Inc. Common Stock (SKYE NASDAQ) stock market data APIs
Skye Bioscience, Inc. Common Stock Financial Data Overview
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Skye Bioscience, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Skye Bioscience, Inc. Common Stock data using free add-ons & libraries
Get Skye Bioscience, Inc. Common Stock Fundamental Data
Skye Bioscience, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -45 034 848
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Skye Bioscience, Inc. Common Stock News

PIMCO Intermediate Municipal Bond Exchange-Traded Fund (MUNI) Shares Cross Above 200 DMA
In trading on Friday, shares of the PIMCO Intermediate Municipal Bond Exchange-Traded Fund ETF (Symbol: MUNI) crossed above their 200 day moving average of $51.51, changing hands as high as $51.73 per...


Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and o...

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and o...

Skye initiated at overweight at Evercore on obesity asset nimacimab
[Wall street.] bodrumsurf * Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE [https://seekingalpha.com/symbol/SKYE]) due to its development of the CB1 inhibitor nimacimab f...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.